Kornimate/medical-research-clean huggingface dataset:
protocol to ease acute cephalalgia in emergency-department

Conditions: Cephalalgia

Summary: the purpose of this study is to determine if the use of a therapeutic and global protocol to relieve cephalalgia is helpful in the emergency department of grenoble university hospital.

cephalalgia is a very common symptom that justifies daily appointment in emergency department. analgesic support, and especially use of oxygen and care of associated symptoms as nausea, photophobia or phonophobia, is very dependent on the physician. the aim of this study is to evaluate the impact of a global analgesic protocol of cephalalgia in emergency department. the investigators included 200 patients aged of 18 up to 55 years old coming in emergency department for headache. pain (visual analogic scale), nausea, photo or phonophobia are recorded each 15 minutes by the patient by using a self-assessment questionnaire. the final diagnosis is recorded by the physician in charge of patient, using international headache society criteria. first 100 patients(group 1) receive usual care. for the last 100 patients (group 2), physician in charge of patients are incited to use a formal protocol that include: putting the patient in a quiet spot, laying down on a stretcher, providing sound proof helmet and light blocking google, administering oxygen therapy 15 l/min during 15 min, and administering etiological headache adapted medication following learned society guidelines. comparison of the data of this 2 groups shall help us to see if the investigators actual analgesic support of cephalalgia is efficient, and if it can be improved by this global analgesic protocol.

Eligibility criteria:
inclusion criteria: * complain about cephalalgia * age 28 to 55 years. exclusion criteria: * fever \> 38,0 °c * history of breath disease, long term use of oxygen therapy, chronic obstructive pulmonary disease, dyspnea * history of cranial traumatism, heart attack, cerebrovascular accident \<3 month * inability to read or understand french. * pregnancy

Keywords: cephalalgia headache migraine pain global treatment oxygen emergency treatment of cephalalgia in emergency department
evaluating ability of ht-6184 to reduce inflammation and pain after third molar extraction

Conditions: Pain

Summary: the goal of this clinical trial is to test the ability of ht-6184 to decrease inflammation and pain in patients after third molar removal. the main question it aims to answer are: * does ht-6184 decrease inflammation in patients after third molar removal? * does ht-6184 decrease pain in patients after third molar removal? participants will be asked to do the following during the clinical trial: * take a single oral dose of ht-6184 or placebo * allow a oral surgeon remove their third molar teeth * blood draws on 5 occurrences * rate their pain intensity * attend two follow-up appointments on day 1 and day 2 after third molar removal * participate in one follow-up phone call 5-7 days after third molar removal


Eligibility criteria:
inclusion criteria: * the candidate is 18 years of age or older, capable of understanding and providing written informed consent to participate and willing to comply with study procedures including providing a blood sample to be saved for potential pharmacokinetic and/or genetic analysis. * the candidate, for any reason, requires surgical extraction of two or more third molars of which at least one is partially or fully impacted in mandibular bone. * the candidate is postmenopausal, surgically sterile or agrees to use an effective and medically acceptable method of contraception for 1 week after his or her last dose of study drug. * if female with child-bearing potential, the candidate must have a negative pregnancy test at screening and pre-surgery on the day of surgery. exclusion criteria: * the candidate typically or on average consumes more than one alcoholic beverage per day. * the candidate is pregnant or nursing. * the candidate has received an investigational drug or used an experimental medical device within 30 days prior to screening. * the candidate has donated 1 or more pints of blood within 8 weeks prior to screening. * the candidate has any hypersensitivity to components of the ht-6184/placebo formulations or the protocol-specified analgesic rescue medication, aspirin or nonsteroidal anti-inflammatory drugs (nsaids). * the candidate has any contraindication to oral surgery or any serious or major medical problems that, in the investigator's opinion, may compromise the safety or the candidate or interfere with the interpretation of study results * the candidate has taken acetaminophen, nsaids (including aspirin) or other medications for pain within 72 hours of the surgical procedure. * the candidate has any abnormal laboratory value or physical finding that, in the opinion of the investigator, may compromise the individual's safety, interfere with interpretation of the study results, or be indicative of an underlying disease state.

Keywords: third molar extraction inflammation biomarkers
psilocybin and depression

Conditions: Severe Depression

Summary: the main aim of the study is to investigate the possible long-term therapeutic effects of psilocybin on the symptoms of severe depression, as well as the brain mechanisms underlying these changes. depression severity is assessed before and after (i.e., 1 week, 3 months and 6 months after) a single dose of psilocybin and compared to respective scores of a group receiving an active placebo, ketamine. brain activity (using functional magnetic resonance imaging) is measured before and one week after drug administration in order to determine whether changes in brain networks related to emotional and self-referential processing correlate with any observed changes in depression scores. further, blood samples will be obtained from the participants and analyzed in order to reveal gene expression and molecular level correlates underlying rapid antidepressant effects, and to identify biomarkers that predict treatment outcome.


Eligibility criteria:
inclusion criteria: 1. major depression of a moderate to severe degree (17+ on the 21-item ham-d). 2. no health-related contraindications. exclusion criteria: 1. current or previously diagnosed psychotic disorder. 2. immediate family member with a diagnosed psychotic disorder. 3. medically significant condition rendering unsuitability for the study (e.g., diabetes, epilepsy, severe cardiovascular disease, hepatic or renal failure etc.). 4. history of suicide attempts. 5. history of mania. 6. current 5-ht2a antagonist antidepressant medication. 7. blood or needle phobia. 8. positive pregnancy test. 9. current drug or alcohol dependence. 10. lack of appropriate use of contraception. 11. breast-feeding.

Keywords: fmri psilocybin ketamine biomarker rapid-acting antidepressants
prehabilitation to revolutionize oncology: telehealth exercise for cognitive triumphs (the protect trial)

Conditions: Breast Cancer; Cancer of the Breast

Summary: the investigators propose to deliver a pilot randomized controlled trial to 40 women newly diagnosed with breast cancer and scheduled to undergo chemotherapy. the current objectives are: 1) to evaluate the preliminary efficacy of the prehabilitation physical activity (pa) intervention delivered by a physical therapist and 2) assess the intervention's feasibility, acceptability, and appropriateness. the long-term goal is to scale this intervention for implementation into the standard of cancer care to prevent, mitigate, and treat cancer-related cognitive decline (crcd).


Eligibility criteria:
eligibility criteria: * diagnosis of breast cancer (stage i-iii). * female. * at least 18 years old. * scheduled to receive curative-intent chemotherapy. * english speaking. * deemed fit to participate in a pa intervention by their oncologist. * not currently participating in another physical activity research study. * low active, defined by self-report as no more than 2 times per week of regular physical activity in the last six months * able to understand and willing to sign an irb-approved written informed consent document.

Keywords: prehabilitation physical activity cancer-related cognitive decline telehealth physical therapy survivorship breast cancer
adrenal myelolipomas case series

Conditions: Adrenal Myelolipoma

Summary: six cases (72 years old female patient, 63 years old male patient, 57 years old female patient, 61 years old female, 72 years old female and 56 years old female) of clinically and radiologically suspected cases of symptomatic adrenal myelolipoma are discussed here. all cases described, presented with flank pain radiating which was suspected as adrenal mass by computed tomography (ct) evaluation. all six cases were histopathologically confirmed as adrenal myelolipoma and managed by laparoscopic surgical excision.

the management in all cases was by laparoscopic adrenalectomy with transperitoneal approach. several retrospective and comparative studies addressed the advantage of minimally invasive adrenalectomy specifically consistent in less postoperative pain, improved patients' satisfaction, shorter hospital stay and recovery time when compared to open adrenalectomy. the laparoscopic transabdominal lateral adrenalectomy is currently the most widely used approach. all our cases were managed by this technique. in our cases initial peritoneal access is achieved 2cm inferior to the right/left costal margin in the midclavicular line, a pressure of 15mmhg is used for co2 insufflation. optical access 10-12mm trocar for the endoscope is placed in the pararectal line 5cm above the umbilicus. under direct vision, the second 10- 12 mm trocar is placed medially to the first one. the third trocar (5mm) is inserted 3 cm above the anterior superior iliac spine in the anterior axillary line. the fourth trocar (5mm) is inserted at the subcostal angle. the key factor for an adequate exposure is an effective dissection of the toldt fascia. vascular structures are ligated with hem-o-lock and subsequent dissection of the adrenal gland with ultrasonic energy. the adrenal is extracted through a gibson-type incision, a penrose drain was left in all cases with its removal upon discharge of the patient.

Eligibility criteria:
inclusion criteria: * patients with adrenal myelolipoma exclusion criteria: * patients without ct scan with myelolipoma

Keywords: adrenal, incidentaloma, myelolipoma, laparoscopy.
analysis of tumors from patients with inherited cancers having had two surgeries (primary + recurrent, or 2 separate types of cancer)

Conditions: Breast Cancer; Ovarian Cancer

Summary: this study will analyze tumor tissue from patients with known genetic mutations (brca1, brca2, chk2, etc) who have tumor tissue available from two surgeries, either primary/recurrent, or two different anatomical sites.

this study will recruit individuals with known brca1 and brca2 mutations or mutations in similar cancer causing genes such as chk2 or palb2 who have had a cancer removed by surgery or biopsied two or more times with available pathological blocks. we wish to enroll individuals who have had more than one surgery or biopsy for cancer allowing us to obtain tumor blocks from more than one time point. such patients would include those with one cancer which has recurred or more than one separate cancer. we will conduct a brief interview with the subject to obtain personal information about medical and treatment history. in addition, we will collect clinical information from their treating physician(s) to correlate molecular findings with clinical responses to treatment and survival and recurrence data. we will collect background clinical information and family history information and a copy of the genetic test results documenting their cancer causing mutation. we will recruit only patients with known brca1 or brca2 mutations or known mutations in other cancer causing genes such as chk2 or palb2 and will not perform genetic testing on non-tumor tissue for any new information on genetic susceptibility in patient samples. enrolled subjects will donate a blood sample that will be obtained locally and shipped to the research laboratory, and this cost will be entirely covered by the research group.

Eligibility criteria:
inclusion criteria: * male or female * age 18 or older * documented mutation in brca1, brca2 or other known cancer causing gene * one or more cancer with available stored tissue blocks or slides * willing to donate 16cc of blood * able to understand english and provide informed consent exclusion criteria: * unable or unwilling to provide informed consent * patient does not have tissue blocks available * minor, under age 18
pk study of yh22189 fdc compared to combination of telmisartan/amlodipine and rosuvastatin

Conditions: Hypertension; Hyperlipidemia

Summary: this is a randomized, open-label, single-dose, 3-treatment, 3-period, 3-sequence crossover design.

this is a 6 by 3 cross-over study to evaluate pharmacokinetics of yh22189 fdc compared to reference telmisartan/amlodipine and rosuvastatin co-administered in three groups enrolling healthy adult male subjects under fasting conditions. subjects will be admitted to the clinic in the evening before day 1. all subjects will receive a single oral dose of yh22189 fdc or telmisartan/amlodipine or rosuvastatin administered in the morning on day 1. all the subjects will remain in the clinical unit until completion of all assessments on day 2 including collection post-dose pk sample. subjects will return to the clinic for pharmacokinetic samples at scheduled time. the three treatment periods will be separated by a washout period.

Eligibility criteria:
inclusion criteria: * healthy male and female with a body mass index(bmi) between 18.5 and 25 kg/m2 * who has not suffered from clinically significant disease * provision of signed written informed consent exclusion criteria: * history of and clinically significant disease * a history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs * administration of other investigational products within 3 months prior to the first dosing * volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ecgs, or vital signs * sitting blood pressure meeting the following criteria at screening: 150 ≥ systolic blood pressure ≤100 (mmhg) and 100 ≥ diastolic blood pressure ≤ 60 (mmhg)
amblyopia and strabismus detection using a pediatric vision scanner

Conditions: Amblyopia; Strabismus

Summary: the purpose of this project is to compare the performance of the pediatric vision scanner (pvs) with the gold standard examination to determine the effectiveness of the pvs at detecting amblyopia and strabismus.


Eligibility criteria:
inclusion: * 2-6 years old * complete ophthalmic examination including cycloplegic refraction conducted on the same day or within 3 months * strabismic, anisometropic, or normal (normal eye examination and refractive error according to aapos guidelines) * parent provides informed consent exclusion: * other ocular disease (includes media opacities, anomalous optic nerve, ptosis, lid hemangioma, conjunctivitis, blepharitis, symptomatic nld) or systemic disease (jia, jra, neurofibromatosis) * developmental delay * strabismus surgery in the past 6 months
neurovascular coupling in patients with early stage diabetes retinopathy

Conditions: Diabetic Retinopathy

Summary: a variety of studies demonstrate that ocular blood flow is altered in diabetes and retinal perfusion abnormalities have been proposed to contribute to the pathogenesis of diabetic retinopathy. various animal and human studies have demonstrated that retinal and optic nerve blood flow increase in response to diffuse luminance flicker. based on studies with erg, this effect has been attributed to augmented activity in the retinal ganglion cells and associated axons indicating a coupling mechanism between neuronal activity and retinal blood flow. whereas a variety of studies describe the effects of flickering light on retinal and optic nerve head blood flow, the knowledge about this coupling in the diabetic retina is sparse. in view of the fact that neural activity and blood flow are strongly coupled in the human retina, one could hypothesize that neurodegenerative changes in the retina could contribute to the vascular dysregulation and in turn lead to changes of ocular perfusion. the investigators set out to investigate whether the coupling of neural activity and blood flow is impaired in patients with early stage diabetic retinopathy compared to those in healthy volunteers.


Eligibility criteria:
inclusion criteria: * men and women aged between 20 and 50 years * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * inclusion criteria of patients are insulin dependent diabetes mellitus (iddm) with non or mild non-proliferative retinopathy. patients with no signs of diabetic retinopathy (level 1) or patients with one or more microaneurysms (level 2) will be included. duration of diabetes is between 5 and 20 years * men and women will be included in equal parts. a pregnancy test will be performed at screening * ametropia of less than 3 diopters and anisometropia of less than 1 diopter exclusion criteria: * non insulin dependent diabetes * maturity onset diabetes of the young (mody diabetes) * any sign of non diabetes induced vascular pathologies, systemic hypertension (defined as systolic blood pressure \> 150 mm hg and diastolic blood pressure \> 90 mm hg.) * presence of intraocular pathology other than diabetic retinopathy * history or family history of epilepsy * pregnancy

Keywords: diabetes ocular blood flow
effect of omega-3 fatty acid on vitamin d activation

Conditions: Hemodialysis Patients; Vitamin D Insufficiency; Vitamin D Deficiency

Summary: extra-renal sources of 1, 25-dihydroxyvitamin d can be increased to normal serum 1, 25-dihydroxyvitamin d levels in chronic kidney disease patients after administration of high dose 25-hydroxyvitamin d. the investigators observed that 1, 25-dihydroxyvitamin d concentrations were significantly increased after 3 months of omega-3 fa supplementation compared to baseline levels without 25-hydroxyvitamin d administration in dialysis patients. in this study, the investigators hypothesized that omega-3 fa and 25-hydroxyvitamin d supplementations may increase 1, 25-dihydroxyvitamin d concentrations much more compared to 25-hydroxyvitamin d supplementation only in hemodialysis patients with insufficient or deficient 25-hydroxyvitamin d levels.


Eligibility criteria:
inclusion criteria: * patients who were treated with hemodialysis for at least 6 months with 25-hydroxyvitamin d \< 30 ng/ml exclusion criteria: * patients with a history of active infection within 3 months, * patients with fish oil or omega-3 fatty acid supplementation within 3 months, * patients with a history of fish, gelatin, and/or omega-3 fatty acid allergies, * patients with a history of hospital admission within 3 months, * patients with a history of bleeding within 3 months, * patients with thrombocytopenia, * patients with current use of warfarin, * patients with an albumin level \< 3.0 g/dl, * patients with malignancy and/or liver cirrhosis

Keywords: omega-3 fatty acid vitamin d ergocalciferol hemodialysis
modification of blood pressure levels and oxygen saturation in patients undergoing conscious sedation

Conditions: Dental Anxiety

Summary: the objective is to compare the changes produced in cardiological and respiratory parameters in three groups of patients undergoing oral surgery. the first group was treated with local anesthesia, a second group with local anesthesia plus oral conscious sedation with midazolam, and a third subject under anesthesia local with inhalation sedation with nitrous oxide. a total of 90 non-cooperative phobic adult patients belonging to the group of patients of the university master in oral surgery, implantology and periodontics of the university of león will be included in this study, after their information and acceptance of verbal and written consent, separated into three groups without significant differences in age, sex, smoking habits, cardiac or respiratory pathologies, and will be treated by advanced procedures of oral surgery, periodontics and implantology such as sinus lift, periodontal surgeries and implant surgeries. they will be randomly divided into three groups of 30 patients each. they will be given a prior consent both of the procedures to be performed and of the sedation procedure to which they will be subjected, if that is the case, without knowing what dose they will be administered. in case of being sedated, they will be informed verbally of the details concerning the procedure.

a total of 90 non-cooperative phobic adult patients will be included in this study, after their information and acceptance of verbal and written consent, separated into three groups without significant differences in age, sex, smoking habits, cardiac or respiratory pathologies, and will be treated by advanced procedures of oral surgery, periodontics and implantology such as sinus lift, periodontal surgeries and implant surgeries. initially, a complete health questionnaire will be filled out in all patients, and partial oxygen saturation (spo2), respiratory rate, respiratory volume in the form of forced vital capacity (fvc), and also forced expiration volume will be recorded as respiratory records (fev) and maximum expiratory flow (pef), and as cardiac registers the heart rate, and the systolic and diastolic blood pressure before starting the procedure, records that will be repeated every 5 minutes during and until the end of it. the parameters will be recorded every 5 minutes, except for the parameters vfc, fev1 and pef that will be recorded exclusively at the beginning and at the end of the procedure.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of phobic patients * not having contraindications to be anesthetized or sedated, and * present an acceptable state of health (asa i and asa ii). exclusion criteria: * clinical conditions; asa iii, asa iv and asa v